glp 1 and sleep GLP-1 receptor agonists, SGLT-2 inhibitors, obstructive apnoea: can new allies face an old enemy? Latest Insights on GLP-1 Therapy

Without the BBB, the CNS is at risk of invasion of toxins, pathogens, immune cells, or ion dysregulation, which would lead to neuronal dysfunction and degeneration [1]

The effect of Valerian on the severity and frequency of hot flashes: A triple-blind randomized clinical trial

The product is gluten-free and contains no added sugars

Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023